Frequently asked questions about FectoVIR®-AAV

Please feel free to browse the Polyplus-transfection Database to find conditions for specific product, cell line or nucleic acid type:

Consult our database

For more information contact us directly at

Contact our experts

What is the chemical structure of FectoVIR®-AAV? What is the difference with PEIpro®?

The FectoVIR®-AAV structure is confidential and a patent has been filled. PEIpro® and FectoVIR®-AAV are different both in terms of molecular structure and formulation.

Where can I find optimized conditions using FectoVIR®-AAV?

You will find starting conditions as well as a range for optimization in the dedicated protocol available in the documentation tab of the FectoVIR®-AAV webpage: If you need further information, please contact our scientific support using our contact us form.

In which cell types FectoVIR®-AAV has been tested?

We have successfully used FectoVIR®-AAV on suspension HEK-293 derivatives (293T, 293F) and high density derivatives (Expi293™ cells). Beta-testers confirmed that FectoVIR®-AAV works well in several commercial and proprietary suspension HEK-293 subclones.

Which serotypes has been produced with FectoVIR®-AAV?

In house, we produce both AAV-2 and AAV-5. More serotypes have been tested by our beta-testers, with comparable yield improvements.

Does FectoVIR®-AAV work in adherent cell culture?

FectoVIR®-AAV shows a remarquable improvement in terms of viral titers in suspension system and is less efficient in adherent systems for which PEIpro® remains the transfection reagent of choice.

Can I use FectoVIR®-AAV to produce recombinant lentiviruses or other types of virus?

For lentivirus production, we recommend PEIpro® the gold standard for virus production as it is currently the best product for this application, both in adherent and suspension cell culture systems.

Is there a residual test available yet?

A residual test assay has been developed. Contact us for more information.

When will GMP grade FectoVIR®-AAV be available?

FectoVIR®-AAV GMP will be available in Q4 2021.

Give your feedback!